We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepVerge Q1 production orders up 39% to £5m

11 Mar 2022 07:00

RNS Number : 4276E
Deepverge PLC
11 March 2022
 

11 March 2022

 

DeepVerge PLC

 

("DeepVerge" or "the Company")

 

 

DeepVerge production orders up 39% worth £5m for Modern Water equipment in Q1

 

Additional installations and extension to wastewater COVID detection trial

 

Multi-year serviced install and monitoring to increase equipment only sales income by 140%

 

 

DeepVerge (LSE:DVRG.L) environmental division, Modern Water, announces production orders up 39% in Q1, worth c£5m (Q1:2021 £3.6m RNS[i]: 17th Feb 2021)) for a range of drinking water testing, contamination and detection of SARS-CoV-2 equipment. This is the biggest Q1 production order ever in Modern Water history and the equipment is expected to be delivered during the current financial year.

 

This equipment is across the range and earmarked for sites including the UK, the EU, China, India and the Middle East. The range of equipment includes Microtox®PD, for real-time detection of SARS-CoV-2 in wastewater treatment plants adding to existing data sampling units installed last year (RNS[ii]: 28th October 2021), extending the trials to April this year.

 

New multi-year installation, monitoring and maintenance recurring revenue model is designed to increase revenue of the existing install-only equipment sales model by 140%. There are 27 Microtox® CTM to be installed in the Middle East and this is the first move away from capital expenditure sales only to multi-year install, monitor and maintain with consumables ("Serviced Lease"), generating recurring revenues of $2.4m (£1.83m)* over a 5 year period in place of a $1m (£0.76m) capital equipment sale. As we transition to the monitoring, we still deliver units, such as those for a Chinese State government department and multiple units on the Yangtze River project which are capital equipment sales.

 

Gerry Brandon CEO DeepVerge plc commented:

"Our Modern Water division continues to grow with the biggest Q1 production order to date, increasing by 39% over Q1, 2021, for existing Microtox® (LX, FX and CTM), Microtrace (trace metal) units and new pathogen detection units, which will go into mass production in the next few months. This is due to the positive test results with Microtox®PD wastewater detection just beginning to realise their full potential with proven market demand having already contributed to part of last year's revenues.

 

The multi-year lease, monitoring and maintenance recurring revenue business model overcomes the seasonal financial cashflow problems experienced by Modern Water when it was a capital equipment sales business. Support and maintenance costs are built into the annual operating expenditure of the client. It offers additional sales opportunities with an established installed base around the world where the Company can offer upgrades and upsell higher value equipment without capital spend by the client, increasing revenues from the value-added real-time monitoring service"

 

 

*Serviced Lease explanation: Of the £5m production orders, 27 Microtox CTM units with a sales value of $1.08m are to be installed on a 60 month serviced lease with monitoring and consumables at $40,000 per month. This is $480,000 over the first 12 months from installation date resulting in $2.4m over 5-years.

 

For further information please contact:

 

DeepVerge plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

About Modern Water (www.modernwater.com)

Modern Water is the environmental division of DeepVerge that has developed and commercialised cutting-edge technology, focused on monitoring of contaminated water and decontamination of wastewater, making recycling of water more efficient. Six countries across the world have legislated that Modern Water monitoring test systems are written into their environmental protection legislation. The division offers an automated real-time contamination detection range of equipment, including Microtox® PD, for the identification of SARS-CoV-2 hotspots and other pathogens in wastewater.

 

 

 

[i] https://www.londonstockexchange.com/news-article/DVRG/prod-n-orders-worth-5m-for-modern-water-equipment/14867523

 

[ii] https://www.londonstockexchange.com/news-article/DVRG/microtox-r-pd-installations-as-part-of-nat-l-trial/15190144

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCJMMTTMTTBTBT
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.